Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma
ENDOVIE
1 other identifier
observational
200
1 country
30
Brief Summary
This is a national observational retrospective multi-site chart review study of patients with advanced, recurrent or metastatic endometrial carcinoma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2022
Shorter than P25 for all trials
30 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 29, 2022
CompletedFirst Posted
Study publicly available on registry
May 6, 2022
CompletedStudy Start
First participant enrolled
May 9, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 22, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
November 22, 2022
CompletedSeptember 6, 2023
September 1, 2023
7 months
April 29, 2022
September 5, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Clinical, biological and treatment characteristics
Description of the data
up to 3 years
Secondary Outcomes (2)
Progession Free Survival real world (rwPFS)
through study completion, an average of 1 year
Overall Survival (OS)
through study completion, an average of 1 year
Study Arms (2)
Cohort 1
Patients in first line treatment (first chemotherapy for advanced, recurrent or metastatic endometrial cancer) in 2019
Cohort 2
Patients in second line treatment (after one prior systemic chemotherapy) in 2019
Interventions
Patients with confirmed advanced, recurrent or metastatic endometrial cancer, treated by chemotherapy in real life-setting, between 1st January 2019 to 31rd December March 2019, in first or second line of chemotherapy.
Eligibility Criteria
The study population musy respect all the inclusion and exclusion criteria.
You may qualify if:
- Adult women ≥ 18 years at index date.
- Documented diagnosis of advanced recurrent or metastatic endometrial cancer not eligible to primary complete surgery. Patients with interval surgery after primary CT may be eligible.
- Index date should represent at least the first\* or second line\*\* chemotherapy systemic treatment and occur between, 1, January 2019 and 31, December 2019.
- do not express refusal to her personal data processing or did not express her refusal for deceased patients.
You may not qualify if:
- No clinical records for tumor imaging or administration of anti-cancer therapy.
- Patients with active malignancy other than EC cancer which contribute significantly to the clinical impairment of the patient during the study period, according to investigator opinion.
- Patients lost to follow-up, defined as patients whose last follow-up information occurs less than two years after index date (unless the patient is deceased).
- Patient did not receive chemotherapy systemic treatment.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- ARCAGY/ GINECO GROUPlead
- Merck Sharp & Dohme LLCcollaborator
Study Sites (30)
Centre Hospitalier Victor Dupouy
Argenteuil, 95100, France
Sainte-Catherine Institut du Cancer Avignon-Provence
Avignon, 84918, France
CHRU Besançon - Hôpital Jean Minjoz
Besançon, 25000, France
Guillaume BABIN
Bordeaux, 33000, France
Hôpital Morvan CHRU de Brest
Brest, 29200, France
Centre d'Oncologie et de Radiothérapie 37
Chambray-lès-Tours, 37175, France
Hôpital Louis Mourier
Colombes, 92700, France
Centre Hospitalier Intercommunal de Créteil
Créteil, 21079, France
CHU de Dijon
Dijon, 21000, France
Centre Georges François Leclerc
Dijon, 21079, France
Groupe Hospitalier Mutualiste de Grenoble
Grenoble, 38028, France
Centre Oscar Lambret
Lille, 59020, France
Centre Léon Bérard
Lyon, 69737, France
ICL - Centre Alexis Vautrin
Nancy, 54000, France
ORACLE - Centre d'Oncologie de Gentilly
Nancy, 54100, France
Hôpital Privé du Confluent
Nantes, 44277, France
Centre Antoine Lacassagne
Nice, 06189, France
Centre ONCOGARD - Institut de cancérologie du Gard
Nîmes, 30029, France
CHR Orléans
Orléans, 45100, France
Institut Curie
Paris, 75005, France
Hôpital Cochin
Paris, 75014, France
Hôpital Européen Georges Pompidou
Paris, 75015, France
Groupe Hospitalier Diaconesses - Croix Saint-Simon
Paris, 75020, France
Centre CARIO - HPCA
Plérin, 22190, France
CHU de Poitiers - Hôpital de la Milétrie
Poitiers, 86021, France
Centre Eugène Marquis
Rennes, 35042, France
ICO - Centre René Gauducheau
Saint-Herblain, 44805, France
ICANS - Institut de cancérologie Strasbourg Europe
Strasbourg, 67033, France
CHU Tours - Hôpital Bretonneau
Tours, 37044, France
Gustave Roussy
Villejuif, 94805, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 29, 2022
First Posted
May 6, 2022
Study Start
May 9, 2022
Primary Completion
November 22, 2022
Study Completion
November 22, 2022
Last Updated
September 6, 2023
Record last verified: 2023-09
Data Sharing
- IPD Sharing
- Will not share